Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Diarrhea source : Jaguarhealth.gcs-web.com save search
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published: 2023-09-12 (Crawled : 12:30) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -1.74%
np-300 drug candidate institute diarrhea health application family funding
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Published: 2023-08-17 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -4.06%
H: 0.41%
C: -2.97%
diarrhea health cancer treatment family crofelemer trial
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published: 2023-08-16 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 6.57%
H: 0.0%
C: 0.0%
diarrhea indicate world sclerosis treatment pharmaceuticals potential
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Published: 2023-08-09 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.85%
H: 0.84%
C: -10.4%
np-300 drug candidate diarrhea health application family funding
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published: 2023-08-07 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.2%
H: 3.33%
C: 0.63%
diarrhea breast cancer crofelemer study
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Published: 2023-08-01 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.02%
H: 0.67%
C: -2.84%
fda drug diarrhea health treatment application crofelemer
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-07-26 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 2.57%
H: 11.58%
C: 6.27%
diarrhea health approval treatment trial
Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People
Published: 2023-06-22 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.81%
H: 2.66%
C: -5.24%
disease media diarrhea health cancer education
Ladenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care
Published: 2023-06-14 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.19%
H: 3.18%
C: 1.71%
ceo diarrhea health cancer care impact
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Published: 2023-05-25 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -3.95%
H: 5.14%
C: -5.07%
diarrhea cancer crofelemer trial
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Published: 2023-05-11 (Crawled : 12:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 23.61%
H: 37.08%
C: 7.87%
fda drug diarrhea approved animal
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Published: 2023-05-09 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.68%
H: 0.54%
C: -6.28%
diarrhea cancer crofelemer trial
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2023-03-30 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -2.24%
H: 9.03%
C: -2.56%
fda veterinary drug conference diarrhea health approved animal cancer
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Published: 2023-02-01 (Crawled : 15:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 3.97%
H: 1.7%
C: -3.61%
treatment drug diarrhea health commercialization license agreement china
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
Published: 2023-01-12 (Crawled : 01:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: -13.79%
plants diarrhea health medical therapeutics cancer
Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Psychoactive Plants
Published: 2023-01-10 (Crawled : 14:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 9.11%
H: 12.02%
C: 2.55%
plants diarrhea health medical therapeutics cancer
Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from Ps
Published: 2023-01-10 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 9.11%
H: 12.02%
C: 2.55%
diarrhea health medical therapeutics cancer
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related Diarrhea
Published: 2022-12-05 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.46%
H: 0.16%
C: -6.97%
pharmaceuticals diarrhea health hiv
Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea
Published: 2022-11-21 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 0.0%
H: 3.46%
C: -5.85%
management diarrhea health symposium cancer
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.